How would involvement from a Venture capitalists or Private equity group look for Paradigm, page-50

Things could fall in to place reasonable quickly once we get confirmation on Stage 2. I doubt FDA will seek to be more onerous on testing than Stage 1 (adrenal testing requirements) and potentially more patient friendly. Either way its NOT likely to be a show stopper just some upside in terms of cash burn.

Some non-dilutive funding is still on the table. The extent of it is unknown. Scott will potentially provide additional options through his channels and then compare it against Med Pharma/Regional deal metrics for best NPV long term outcomes. They are not shying away from the FY24 Q4 deadline they set.